319 related articles for article (PubMed ID: 25112436)
1. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
2. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
3. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
Yu Y; Cai W; Pei CG; Shao Y
Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
[TBL] [Abstract][Full Text] [Related]
4. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
6. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Saraswati S; Kanaujia PK; Kumar S; Kumar R; Alhaider AA
Mol Cancer; 2013 Jul; 12():82. PubMed ID: 23895055
[TBL] [Abstract][Full Text] [Related]
7. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
8. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
[TBL] [Abstract][Full Text] [Related]
9. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
10. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
Yu Y; Yu J; Pei CG; Li YY; Tu P; Gao GP; Shao Y
Int J Clin Exp Pathol; 2015; 8(9):10355-64. PubMed ID: 26617743
[TBL] [Abstract][Full Text] [Related]
14. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
15. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation.
Mu X; Shi W; Sun L; Li H; Jiang Z; Zhang L
Molecules; 2012 Jun; 17(6):6854-68. PubMed ID: 22669041
[TBL] [Abstract][Full Text] [Related]
16. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
17. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
18. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
19. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
Saraswati S; Kumar S; Alhaider AA
Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
[TBL] [Abstract][Full Text] [Related]
20. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M
Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]